These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22222036)

  • 1. Small molecule inhibitors of BRAF in clinical trials.
    Zambon A; Niculescu-Duvaz I; Niculescu-Duvaz D; Marais R; Springer CJ
    Bioorg Med Chem Lett; 2012 Jan; 22(2):789-92. PubMed ID: 22222036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF in melanoma: current strategies and future directions.
    Salama AK; Flaherty KT
    Clin Cancer Res; 2013 Aug; 19(16):4326-34. PubMed ID: 23770823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Light-controlled inhibition of BRAFV600E kinase.
    Hoorens MWH; Ourailidou ME; Rodat T; van der Wouden PE; Kobauri P; Kriegs M; Peifer C; Feringa BL; Dekker FJ; Szymanski W
    Eur J Med Chem; 2019 Oct; 179():133-146. PubMed ID: 31252305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options.
    Villanueva J; Vultur A; Herlyn M
    Cancer Res; 2011 Dec; 71(23):7137-40. PubMed ID: 22131348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent progress in the identification of BRAF inhibitors as anti-cancer agents.
    El-Nassan HB
    Eur J Med Chem; 2014 Jan; 72():170-205. PubMed ID: 24424304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition.
    Zimmer L; Hillen U; Livingstone E; Lacouture ME; Busam K; Carvajal RD; Egberts F; Hauschild A; Kashani-Sabet M; Goldinger SM; Dummer R; Long GV; McArthur G; Scherag A; Sucker A; Schadendorf D
    J Clin Oncol; 2012 Jul; 30(19):2375-83. PubMed ID: 22614973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
    Montagut C; Sharma SV; Shioda T; McDermott U; Ulman M; Ulkus LE; Dias-Santagata D; Stubbs H; Lee DY; Singh A; Drew L; Haber DA; Settleman J
    Cancer Res; 2008 Jun; 68(12):4853-61. PubMed ID: 18559533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting BRAF in melanoma: biological and clinical challenges.
    Mandalà M; Voit C
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma.
    Cohen JV; Sullivan RJ
    Clin Cancer Res; 2019 Oct; 25(19):5735-5742. PubMed ID: 30992297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma.
    Pérez-Lorenzo R; Zheng B
    Biosci Rep; 2012 Feb; 32(1):25-33. PubMed ID: 21981139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism and inhibition of BRAF kinase.
    Gunderwala A; Cope N; Wang Z
    Curr Opin Chem Biol; 2022 Dec; 71():102205. PubMed ID: 36067564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of potential inhibitors targeting BRAF-V600E mutant melanoma cells.
    Kadioglu O; Saeed MEM; Greten HJ; Mayr K; Schrama D; Roos WP; Efferth T
    J Am Acad Dermatol; 2021 Apr; 84(4):1086-1089. PubMed ID: 32707252
    [No Abstract]   [Full Text] [Related]  

  • 13. Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.
    Jalili A; Wagner C; Pashenkov M; Pathria G; Mertz KD; Widlund HR; Lupien M; Brunet JP; Golub TR; Stingl G; Fisher DE; Ramaswamy S; Wagner SN
    J Natl Cancer Inst; 2012 Nov; 104(21):1673-9. PubMed ID: 22997239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
    Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
    Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.
    Jang S; Atkins MB
    Clin Pharmacol Ther; 2014 Jan; 95(1):24-31. PubMed ID: 24080641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocyte growth factor in the neighborhood reverses resistance to BRAF inhibitor in melanoma.
    Nickoloff BJ; Vande Woude G
    Pigment Cell Melanoma Res; 2012 Nov; 25(6):758-61. PubMed ID: 22974232
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.
    Holderfield M; Deuker MM; McCormick F; McMahon M
    Nat Rev Cancer; 2014 Jul; 14(7):455-67. PubMed ID: 24957944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents.
    Niculescu-Duvaz D; Niculescu-Duvaz I; Suijkerbuijk BM; Ménard D; Zambon A; Davies L; Pons JF; Whittaker S; Marais R; Springer CJ
    Bioorg Med Chem; 2013 Mar; 21(5):1284-304. PubMed ID: 23376011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The genesis of Zelboraf: targeting mutant B-Raf in melanoma.
    Davis MJ; Schlessinger J
    J Cell Biol; 2012 Oct; 199(1):15-9. PubMed ID: 23027900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.